HTR1A and major depressive disorder: Here we compare the effects of vilazodone, a high efficacy serotonin reuptake inhibitor with potent 5-HT1A partial agonist properties, to fluoxetine, the prototype selective serotonin reuptake inhibitor (SSRI) approved for the treatment of depression, in the novelty suppressed feeding (NSF) paradigm.